Last reviewed: July 2, 2026
Last updated: July 2, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
Mounjaro and Wegovy represent two distinct pathways in modern weight management therapy. Mounjaro (tirzepatide) activates both GLP-1 and GIP receptors, while Wegovy (semaglutide) targets only the GLP-1 pathway. Clinical evidence shows tirzepatide users experience more substantial weight reduction on average, with some studies reporting up to 22% body weight loss compared to Wegovy's typical 17% reduction.
Understanding the Mechanism: GIP and GLP-1 Receptor Action
Mounjaro works as a dual-action medication that activates two hormone receptors simultaneously. The GIP receptor helps regulate appetite and blood sugar, while the GLP-1 receptor slows gastric emptying and increases fullness signals to the brain. Wegovy, by contrast, only activates the GLP-1 receptor, which explains why some patients respond better to tirzepatide's two-pronged approach.
Your individual genetic makeup influences how effectively each medication works for your body. The Precision Peptide Genetic Test from PlexusDx analyzes your GIPR rs1800437 and GLP1R rs6923761 variants, among other critical peptide-pathway markers. This genetic insight helps determine whether a dual-receptor therapy like tirzepatide might produce superior outcomes for your specific metabolism.
Clinical Weight Loss Comparison: Real Trial Data
The SURMOUNT trials for tirzepatide demonstrated that patients achieved 22% body weight reduction at the highest maintenance dose, compared to placebo's 2.4% reduction. Wegovy trials (STEP program) showed 17% average body weight loss at the maximum dose. The difference of approximately 5 percentage points reflects tirzepatide's dual-receptor mechanism and suggests stronger appetite suppression and metabolic effects over the semaglutide-only approach.
Individual responses vary significantly based on genetics, lifestyle, and baseline metabolic health. Some patients lose weight faster on Wegovy, while others plateau and benefit from switching to tirzepatide or combining treatments. PlexusDx offers the GLP-Squared Injection—a dual compound combining both semaglutide and tirzepatide—for patients seeking maximum flexibility and personalized dosing.
Cost and Access: Comparing Treatment Affordability
Mounjaro typically costs between $900 and $1,300 per month through traditional insurance or retail pharmacy channels, often placing it out of reach for uninsured patients. PlexusDx compounded Tirzepatide Injection starts at $249 per month through licensed 503A compounding pharmacies, making tirzepatide accessible without insurance requirements or membership fees. Both HSA and FSA accounts can cover this cost, increasing affordability for eligible patients.
Wegovy carries similar market pricing constraints, creating barriers to long-term therapy for many individuals. PlexusDx Compounded Semaglutide Injection begins at $149 per month, offering the most affordable GLP-1 option. Your dose may need to go up during treatment. Your price won't—PlexusDx maintains flat monthly pricing across all dose levels.
Which Should You Choose: Personalized Decision Framework
Selection between Mounjaro and Wegovy depends on your genetic predispositions, previous medication responses, baseline health metrics, and weight loss goals. Patients with strong GIP receptor sensitivity (identified through genetic testing) often experience superior results with tirzepatide. Those new to GLP-1 therapy might start with semaglutide to assess tolerance before advancing to dual-receptor compounds.
PlexusDx recommends genetic testing after your first month of treatment to optimize your long-term strategy. The Precision Peptide Genetic Test ($99 add-on) maps 14 peptide pathways across 49 distinct peptides, providing 150+ genetic insights specific to your weight loss biology. This data guides whether tirzepatide injection, semaglutide, or combination therapy (GLP-Squared) produces the fastest, most sustainable results for your body.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $249/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
Does tirzepatide produce faster weight loss than semaglutide?
Clinical trials show tirzepatide (Mounjaro) achieves approximately 5% greater body weight reduction on average compared to semaglutide (Wegovy). However, individual response times vary—some patients see significant results within 4–8 weeks on either medication. PlexusDx compounded tirzepatide injection starts at $249/month and allows dose adjustments without price increases.
What evidence supports tirzepatide's superior weight loss?
The SURMOUNT-1 trial (the largest tirzepatide study) reported 22.5% body weight reduction at 21 mg weekly, versus STEP-1 (Wegovy's pivotal trial) showing 17.4% reduction at 2.4 mg weekly. Tirzepatide's dual GIP/GLP-1 action creates stronger satiety signals and metabolic suppression, explaining the approximately 5-point difference in average weight loss.
Can I get tirzepatide through PlexusDx without insurance?
Yes. PlexusDx Compounded Tirzepatide Injection serves all 50 states with no insurance requirement and no membership fees. Pricing starts at $249 per month through licensed 503A compounding pharmacies. HSA and FSA accounts are eligible for payment, and your dose can increase without any price increase.
Are there differences in side effects between Mounjaro and Wegovy?
Both medications produce similar gastrointestinal side effects (nausea, vomiting, constipation, diarrhea), though tirzepatide users sometimes report slightly higher initial nausea rates. Side effects typically diminish after 4–6 weeks as the body adapts. Genetic factors influence side effect severity, which is why PlexusDx Precision Peptide testing can help predict your tolerability profile.
How does genetic testing improve my weight loss results?
PlexusDx Precision Peptide Genetic Test analyzes variants like GIPR rs1800437 and GLP1R rs6923761 to reveal how effectively your body responds to GIP and GLP-1 signaling. This $99 test (added after month one) guides whether tirzepatide injection, semaglutide, or PlexusDx GLP-Squared dual therapy will maximize your weight loss across 14 peptide pathways and 150+ genetic insights.
Related Reading
Pricing and availability current as of July 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
Can I Eat Before Taking Wegovy? A Detailed Guide to Meal Timing and Nutrition
Can I Eat Before Taking Wegovy? A Detailed Guide to Meal Timing and Nutrition